참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Ethylenediaminetetraacetic Acid | HCID 6049 | — |
| 반응물 | Succinate | HCID 160419 | — |
| 반응물 | Sulfo-SMCC sodium | HCID 4618794 | — |
| 반응물 | 1-[4-[(2,5-Dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid | HCID 4618795 | — |
| 용매 | Dimethylacetamide | HCID 31374 | — |
| 용매 | Hepps | HCID 85255 | — |
| 생성물 | Succinimidyl 4-(N-maleimidomethyl)cyclohexanecarboxylate | HCID 125175 | — |
반응 단계
The conjugates of the present invention can also be prepared by in situ process according to the following procedures. Antibodies (21 clones) were conjugated to DM1 using the sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) linker Stock solutions of DM1 and sulfo-SMCC heterobifunctional linker were prepared in DMA. Sulfo-SMCC and DM1 thiol were mixed together to react for 10 minutes at 25° C. in DMA containing 40% v/v of aqueous 50 mM succinate buffer, 2 mM EDTA, pH 5.0, at the ratio of DM1 to linker of 1.3:1 mole equivalent and a final concentration of DM1 of 1.95 mM. The antibody was then reacted with an aliquot of the reaction to give a mole equivalent ratio of SMCC to Ab of around 6.5:1 under final conjugation conditions of 2.5 mg/mL of Ab in 50 mM EPPS, pH 8.0 and 10% DMA (v/v). After approximately 18 hours at 25° C., the conjugation reaction mixture was purified using a SEPHADEX™ G25 column equilibrated with 10 mM succinate, 250 mM glycine, 0.5% sucrose, 0.01% Tween 20, pH 5.5.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US09415118B2 |
|---|
| 출처 데이터셋 | uspto-grants-2016_08 |
|---|
| ORD ID | ord-0646637369f04b9a99367913c136d306 |
|---|
| 출처 메모 | uspto-grants-2016_08 |
|---|